Literature DB >> 1709374

Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies.

B H Chong1, X P Du, M C Berndt, S Horn, C N Chesterman.   

Abstract

Sera of 12 patients with quinine/quinidine-induced thrombocytopenia showed drug-dependent antibody binding to glycoprotein (GP) Ib-IX complex. The reaction with GPIb-IX complex of 11 of these 12 sera was strongly inhibited by the complex-specific monoclonal antibodies (MoAbs) AK1 and SZ1. The exception was a quinine-induced serum designated BU. The reaction of the six quinidine-induced sera was also partially blocked by an anti-GPIX MoAb, FMC25. Only 3 of the 12 patient sera showed drug-dependent antibody binding to GPIIb/IIIa, which was strongly inhibited by the anti-GPIIIa MoAb 22C4, and the anti-GPIIb alpha MoAb SZ22. With detergent-solubilized Serratia metalloprotease-treated platelets, quinine/quinidine-induced sera, except BU, immunoprecipitated a membrane-bound proteolytic fragment of GPIb-IX complex. In contrast, BU immunoprecipitated glycocalicin and a 40-Kd peptide tail fragment of GPIb alpha from the cell supernatant. Using purified GPIb-IX complex or its components as the target antigen, all the quinine-induced sera, except BU, immunoprecipitated GPIb-IX complex but failed to immunoprecipitate GPIb, GPIX, or the complex reformed from GPIb and GPIX. The quinidine-induced sera strongly immunoprecipitated purified GPIb-IX complex, weakly immunoprecipitated purified GPIX and the recombined complex, but did not immunoprecipitate purified GPIb. The combined data suggest that one quinine-dependent antibody (BU) recognizes an epitope in the peptide tail region of GPIb alpha and the other five quinine-dependent antibodies react with a complex-specific epitope on the membrane-associated region of GPIb-IX complex, whereas each of the six quinidine-induced sera contain two drug-dependent antibodies, one reactive with the GPIb-IX complex-specific epitope and the other reactive with GPIX. The binding domain(s) on GPIIb/IIIa for the quinine/quinidine-dependent antibodies appear to be sterically close to the epitopes for 22C4 and SZ22.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709374

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA.

Authors:  Julie A Peterson; Tamara N Nelson; Adam J Kanack; Richard H Aster
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

2.  Quinine-induced severe thrombocytopenia: the importance of taking a detailed drug history.

Authors:  Muhajir Mohamed; Robert Hayes
Journal:  BMJ Case Rep       Date:  2013-10-03

3.  Mechanism of quinine-dependent monoclonal antibody binding to platelet glycoprotein IIb/IIIa.

Authors:  Daniel W Bougie; Julie Peterson; Mark Rasmussen; Richard H Aster
Journal:  Blood       Date:  2015-09-09       Impact factor: 22.113

4.  Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies.

Authors:  Daniel W Bougie; Peter R Wilker; Richard H Aster
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 5.  Drug-induced thrombocytopenia.

Authors:  Gian Paolo Visentin; Chao Yan Liu
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

Review 6.  A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia.

Authors:  D M Arnold; S Kukaswadia; I Nazi; A Esmail; L Dewar; J W Smith; T E Warkentin; J G Kelton
Journal:  J Thromb Haemost       Date:  2013-01       Impact factor: 5.824

7.  Effects of vitamin b6 therapy for sepsis patients with linezolid-associated cytopenias: a retrospective study.

Authors:  Jie Deng; Long-Xiang Su; Zhi-Xin Liang; Li-Ling Liang; Peng Yan; Yan-Hong Jia; Xin-Gang Zhang; Dan Feng; Li-Xin Xie
Journal:  Curr Ther Res Clin Exp       Date:  2013-06

8.  Bilateral exudative retinal detachments due to thrombotic microangiopathy associated with intravenous abuse of Opana ER.

Authors:  Fazila Aseem; Brian G Zamora; Levi Kauffman; Peter J Miller; Vishak J John
Journal:  Am J Ophthalmol Case Rep       Date:  2018-06-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.